<DOC>
	<DOCNO>NCT00115414</DOCNO>
	<brief_summary>The purpose study provide data safety efficacy pegfilgrastim administer day versus next day chemotherapy , measure duration grade 4 neutropenia .</brief_summary>
	<brief_title>Same Day Dosing Pegfilgrastim Breast Cancer Patients Undergoing Chemotherapy ( TAC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Breast cancer , previously untreated Active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral ) within 72 hour chemotherapy Prior malignancy within last 5 year , exception surgically cure basal/squamous skin cell carcinoma , ductal carcinoma situ breast and/or carcinoma cervix situ History impair cardiac status ( e.g. , severe heart disease , cardiomyopathy congestive heart failure ) Major surgery within 2 week prior randomization Previous exposure cytokine within two week prior Concurrent use investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>NeulastaÂ®</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>TAC</keyword>
	<keyword>Amgen</keyword>
</DOC>